Primary Care Vasculitis Polymyalgia Rheumatica and Giant Cell Arteritis

被引:2
|
作者
Pioro, Mathilde H. [1 ,2 ]
机构
[1] Cleveland Clin, Orthoped & Rheumatol Inst, Dept Rheumatol, 9500 Euclid Ave A50, Cleveland, OH 44195 USA
[2] Case Western Reserve Univ, Cleveland Clin, Lerner Coll Med, 9500 Euclid Ave A50, Cleveland, OH 44195 USA
来源
PRIMARY CARE | 2018年 / 45卷 / 02期
关键词
Polymyalgia rheumatica; Giant cell arteritis; Temporal artery biopsy; Corticosteroids; Tocilizumab; SERONEGATIVE SYMMETRICAL SYNOVITIS; ERYTHROCYTE SEDIMENTATION-RATE; POSITRON-EMISSION-TOMOGRAPHY; PLACEBO-CONTROLLED TRIAL; PITTING EDEMA RS3PE; C-REACTIVE PROTEIN; DOUBLE-BLIND; TEMPORAL ARTERITIS; FOLLOW-UP; CLINICAL-FEATURES;
D O I
10.1016/j.pop.2018.02.007
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Polymyalgia rheumatica (PMR) and giant cell arteritis (GCA) are related inflammatory diseases of adults aged 50 years or older. The diagnosis of PMR is based on morning stiffness, proximal shoulder and pelvic girdle pain, and functional impairment. GCA is characterized by headache, jaw claudication, and visual disturbances. Constitutional symptoms and elevated inflammatory markers are common to both conditions. Temporal artery biopsy remains the gold standard for diagnosis of GCA. Glucocorticoids are the cornerstone of therapy, with tapering regimens individualized to the patient. Prompt diagnosis and treatment are essential to avert vision loss in GCA. Tocilizumab increases remission rates in GCA.
引用
收藏
页码:305 / +
页数:20
相关论文
共 50 条